Homepage / Press Release

Press Release

2023

01

Aug

MediWound Announces Commercial Launch of NexoBrid® in Japan
10

Jul

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
03

Jul

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
30

May

MediWound Reports First Quarter 2023 Financial Results
10

May

MediWound Announces an Additional $10 Million Award from BARDA
01

May

Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Lymph Node
19

Apr

Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
18

Apr

Gamida Cell Announces Launch of Public Offering of Securities
17

Apr

Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
27

Mar

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
22

Mar

Frunexian בטיפול בחולים המחוברים ל- ECMO מיקוד תוכנית הפיתוח של
05

Mar

Elicio Therapeutics Anounces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Imunotherapy, ELI-02, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer athe ASCO Anual Meting Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
05

Feb

MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
05

Jan

Elicio Therapeutics Anounces Completion of Merger with Angion Biomedica

2022

2021

2020

2019

2018

2017